These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37416744)

  • 1. Current progress in perioperative chemotherapy for biliary tract cancer.
    Ioka T; Shindo Y; Ueno M; Nagano H
    Ann Gastroenterol Surg; 2023 Jul; 7(4):565-571. PubMed ID: 37416744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
    Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
    BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial.
    Goetze TO; Bechstein WO; Bankstahl US; Keck T; Königsrainer A; Lang SA; Pauligk C; Piso P; Vogel A; Al-Batran SE
    BMC Cancer; 2020 Feb; 20(1):122. PubMed ID: 32059704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
    Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
    J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review.
    Yoo C; Shin SH; Park JO; Kim KP; Jeong JH; Ryoo BY; Lee W; Song KB; Hwang DW; Park JH; Lee JH
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
    Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
    Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100334. PubMed ID: 33592563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
    Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
    Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy for Biliary Tract Cancer].
    Woo SM
    Korean J Gastroenterol; 2017 Mar; 69(3):172-176. PubMed ID: 28329919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy of biliary tract cancers.
    Kefas J; Bridgewater J; Vogel A; Stein A; Primrose J
    Ther Adv Med Oncol; 2023; 15():17588359231163785. PubMed ID: 37007632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.
    Ramjeesingh R; Chaudhury P; Tam VC; Roberge D; Lim HJ; Knox JJ; Asselah J; Doucette S; Chhiber N; Goodwin R
    Curr Oncol; 2023 Jul; 30(8):7132-7150. PubMed ID: 37622998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for cholangiocarcinoma: An update.
    Ramírez-Merino N; Aix SP; Cortés-Funes H
    World J Gastrointest Oncol; 2013 Jul; 5(7):171-6. PubMed ID: 23919111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
    Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
    [No Abstract]   [Full Text] [Related]  

  • 19. A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
    Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
    Ann Surg Oncol; 2023 Nov; 30(12):7331-7337. PubMed ID: 37450093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
    Williams KJ; Picus J; Trinkhaus K; Fournier CC; Suresh R; James JS; Tan BR
    HPB (Oxford); 2010 Aug; 12(6):418-26. PubMed ID: 20662793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.